HLA class I-compatible killer peptides or HLA class II-compliant helper peptides targeting KRAS, SMAD4, or TP53 were predicted from cancer genomic profiles (Table 2), which are pancreatic cancer driver genes frequently identified as pathogenic mutations [23]. This evidence concerns the gene KRAS and cancer.